跳至主要内容
临床试验/EUCTR2019-001324-35-DE
EUCTR2019-001324-35-DE进行中(未招募)1 期

Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE) - AD-HERE

Friedrich-Schiller-University Jena0 个研究点目标入组 80 人开始时间: 2019年9月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Signed and dated informed consent has been obtained.
  • 2. Clinical diagnosis of chronic mild-to-moderate hand dermatitis with or without atopic etiology or background (according to IGA: at least mild at Visit 1).
  • 3. Subject(male or female) aged from 18 to 65 years.
  • 4. In overall good health including well controlled diseases as determined by medical history, physical examination, vital signs and clinical laboratory.
  • 5. Female subjects must be of either:
  • non-childbearing potential, post-menopausal, or have a confirmed clinical history of sterility or,
  • childbearing potential, provided there is a confirmed negative urine pregnancy test prior to exposure, to rule out pregnancy
  • Female subjects of childbearing potential must be willing to use highly effective methods of contraception to avoid causing pregnancy from enrollment and until the last visit (V3).
  • Female subjects must not be breastfeeding.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • female who is pregnant or breast-feeding
  • Systemic treatment with immunosuppressive drugs, retinoids or corticosteroids within 8 weeks prior to randomization.
  • Phototherapy (PUVA or UVB) on the hands within 4 weeks prior to randomization.
  • Topical applied treatment with immunomodulators (e.g. pimecrolimus or tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization.
  • Use of other treatment on the hands during the clinical trial except for the use of investigational medicinal product (IMP) and emollient provided by sponsor during the clinical trial.
  • Use of systemic antobiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization.
  • Concurrent skin diseases on the Hands and/or Integument with acute flare and/or Skin lesions within the last 8 weeks.
  • Current diagnosis of eczema on the integument except for the hands.
  • Current diagnosis of exfoliative dermatitis.
  • Current diagnosis of glaucoma or cataract.
  • Significant clinical infection on the hands which requires antibiotic treatment.
  • Known or suspected hypersensitivity to component(s) of the IMP.
  • Subjects with history of an immunocompromising disease (e.g. lymphoma, HIV).
  • Former participation on this clinical trial.
  • Current participation in any other interventional clinical trial.
  • Subjects known or, in the opinion of the investigator, are unlikely to comply with the Clinical Trial Protocol (e.g. alcoholism, drug dependency or psychotic state).
  • Close affiliation with the investigator or other employees of the trial site (e.g. a close relative) or persons working at LEO PharmaA/S or Bayer Consumer Care AG or subject is an employee of Klinik für Hautkrankheiten Jena.

研究者

发起方
Friedrich-Schiller-University Jena

相似试验